These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

404 related items for PubMed ID: 26260130

  • 1. In vivo evolution of resistance of Pseudomonas aeruginosa strains isolated from patients admitted to an intensive care unit: mechanisms of resistance and antimicrobial exposure.
    Solé M, Fàbrega A, Cobos-Trigueros N, Zamorano L, Ferrer-Navarro M, Ballesté-Delpierre C, Reustle A, Castro P, Nicolás JM, Oliver A, Martínez JA, Vila J.
    J Antimicrob Chemother; 2015 Nov; 70(11):3004-13. PubMed ID: 26260130
    [Abstract] [Full Text] [Related]

  • 2. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 3. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI).
    Antimicrob Agents Chemother; 2011 May; 55(5):1906-11. PubMed ID: 21357294
    [Abstract] [Full Text] [Related]

  • 4. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM, Choi JY, Lee JY, Kang CI, Chung DR, Peck KR, Song JH, Ko KS.
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373200
    [Abstract] [Full Text] [Related]

  • 5. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 6. Carbapenem resistance mechanisms in Pseudomonas aeruginosa: alterations of porin OprD and efflux proteins do not fully explain resistance patterns observed in clinical isolates.
    El Amin N, Giske CG, Jalal S, Keijser B, Kronvall G, Wretlind B.
    APMIS; 2005 Mar; 113(3):187-96. PubMed ID: 15799762
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms of resistance in clinical isolates of Pseudomonas aeruginosa less susceptible to cefepime than to ceftazidime.
    Campo Esquisabel AB, Rodríguez MC, Campo-Sosa AO, Rodríguez C, Martínez-Martínez L.
    Clin Microbiol Infect; 2011 Dec; 17(12):1817-22. PubMed ID: 21599797
    [Abstract] [Full Text] [Related]

  • 8. Clinical, microbiologic, and epidemiologic characteristics of Pseudomonas aeruginosa infections in a University Hospital, Malatya, Turkey.
    Yetkin G, Otlu B, Cicek A, Kuzucu C, Durmaz R.
    Am J Infect Control; 2006 May; 34(4):188-92. PubMed ID: 16679175
    [Abstract] [Full Text] [Related]

  • 9. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M, Mills JC, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [Abstract] [Full Text] [Related]

  • 10. Diversity of β-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study.
    Llanes C, Pourcel C, Richardot C, Plésiat P, Fichant G, Cavallo JD, Mérens A, GERPA Study Group.
    J Antimicrob Chemother; 2013 Aug; 68(8):1763-71. PubMed ID: 23629014
    [Abstract] [Full Text] [Related]

  • 11. In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of Intensive Care Unit patients with nosocomial pneumonia and receiving antipseudomonal therapy.
    Riou M, Carbonnelle S, Avrain L, Mesaros N, Pirnay JP, Bilocq F, De Vos D, Simon A, Piérard D, Jacobs F, Dediste A, Tulkens PM, Van Bambeke F, Glupczynski Y.
    Int J Antimicrob Agents; 2010 Dec; 36(6):513-22. PubMed ID: 20926262
    [Abstract] [Full Text] [Related]

  • 12. Spread of efflux pump-overexpressing, non-metallo-beta-lactamase-producing, meropenem-resistant but ceftazidime-susceptible Pseudomonas aeruginosa in a region with blaVIM endemicity.
    Pournaras S, Maniati M, Spanakis N, Ikonomidis A, Tassios PT, Tsakris A, Legakis NJ, Maniatis AN.
    J Antimicrob Chemother; 2005 Oct; 56(4):761-4. PubMed ID: 16115825
    [Abstract] [Full Text] [Related]

  • 13. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):658-663. PubMed ID: 29149337
    [Abstract] [Full Text] [Related]

  • 14. Efflux system overexpression and decreased OprD contribute to the carbapenem resistance among extended-spectrum beta-lactamase-producing Pseudomonas aeruginosa isolates from a Chinese university hospital.
    Liu Y, Li XY, Wan LG, Jiang WY, Li FQ, Yang JH.
    Microb Drug Resist; 2013 Dec 01; 19(6):463-8. PubMed ID: 23865862
    [Abstract] [Full Text] [Related]

  • 15. Doripenem versus Pseudomonas aeruginosa in vitro: activity against characterized isolates, mutants, and transconjugants and resistance selection potential.
    Mushtaq S, Ge Y, Livermore DM.
    Antimicrob Agents Chemother; 2004 Aug 01; 48(8):3086-92. PubMed ID: 15273124
    [Abstract] [Full Text] [Related]

  • 16. Beta-lactam resistance mechanisms in Pseudomonas aeruginosa strains causing bloodstream infections: comparative results between Brazilian and American isolates.
    Fehlberg LC, Xavier DE, Peraro PP, Marra AR, Edmond MB, Gales AC.
    Microb Drug Resist; 2012 Aug 01; 18(4):402-7. PubMed ID: 22455540
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries.
    Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN.
    J Antimicrob Chemother; 2014 Jul 01; 69(7):1804-14. PubMed ID: 24603963
    [Abstract] [Full Text] [Related]

  • 18. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
    Antimicrob Agents Chemother; 2010 Mar 01; 54(3):1213-7. PubMed ID: 20086158
    [Abstract] [Full Text] [Related]

  • 19. Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
    Aghazadeh M, Hojabri Z, Mahdian R, Nahaei MR, Rahmati M, Hojabri T, Pirzadeh T, Pajand O.
    Infect Genet Evol; 2014 Jun 01; 24():187-92. PubMed ID: 24694825
    [Abstract] [Full Text] [Related]

  • 20. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
    Aktaş Z, Satana D, Kayacan C, Can B, Gönüllü N, Küçükbasmacı O.
    Mikrobiyol Bul; 2012 Jul 01; 46(3):386-97. PubMed ID: 22951651
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.